6,133 results match your criteria Acta Oncologica[Journal]


Is there a role for repeating PSMA PET/CT after a negative scan in biochemical recurrent prostate cancer?

Acta Oncol 2020 Jul 10:1-4. Epub 2020 Jul 10.

Urology Department, University Clinics of Brussels, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1790655DOI Listing

Toxicity of internal mammary irradiation in breast cancer. Are concerns still justified in times of modern treatment techniques?

Acta Oncol 2020 Jul 3:1-9. Epub 2020 Jul 3.

Department of Radiation Oncology, Technical University of Munich (TUM), München, Germany.

The purpose of this study was to estimate the additional risk of side effects attributed to internal mammary node irradiation (IMNI) as part of regional lymph node irradiation (RNI) in breast cancer patients and to compare it with estimated overall survival (OS) benefit from IMNI. Treatment plans ( = 80) with volumetric modulated arc therapy (VMAT) were calculated for 20 patients (4 plans per patient) with left-sided breast cancer from the prospective GATTUM trial in free breathing (FB) and in deep inspiration breath hold (DIBH). We assessed doses to organs at risk ((OARs) lung, contralateral breast and heart) during RNI with and without additional IMNI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1787509DOI Listing

Characterization of uveal melanoma clinical trial design: a systematic review to establish an elusive standard of care.

Acta Oncol 2020 Jul 1:1-8. Epub 2020 Jul 1.

Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA.

: There is currently no FDA or EMA-approved standard of care for metastatic uveal melanoma.: A systematic review of all interventional uveal melanoma trials on the ClinicalTrials.gov database and EU Clinical Trials Register was conducted from January 15, 2019 through November 30, 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1787508DOI Listing

Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up.

Acta Oncol 2020 Jun 30:1-8. Epub 2020 Jun 30.

Department of Radiation Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland.

The optimal activity of radioiodine (I-131) administered for ablation therapy in papillary and follicular thyroid cancer after thyroidectomy remains unknown in a long-term (> 10 year) follow-up. Some, shorter follow-up studies suggest that activities 1.1 GBq and 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1785003DOI Listing

Clinical trials in the era of precision cancer medicine - for the few or for the many?

Authors:
Hege G Russnes

Acta Oncol 2020 Jul 24;59(7):731-732. Epub 2020 Jun 24.

Head of Experimental Pathology and Trial Support, Department of Pathology, Clinic for Laboratory Medicine, Oslo University Hospital, Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1777582DOI Listing

Evaluation of the stage classification of anal cancer by the TNM 8th version versus the TNM 7th version.

Acta Oncol 2020 Jun 23:1-8. Epub 2020 Jun 23.

Department of Oncology, Skåne University Hospital, Lund, Sweden.

: The UICC TNM 7th edition introduced stage groups for anal cancer which in 2019 has not yet come into general use. The new TNM 8th edition from 2016 defines 7 sub-stages. Background data for these changes are lacking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1778180DOI Listing

Automatic segmentation of pelvic organs-at-risk using a fusion network model based on limited training samples.

Acta Oncol 2020 Jun 22:1-7. Epub 2020 Jun 22.

Department of Radiation Oncology, The First Medical Center of People's Liberation Army General Hospital, Beijing, China.

Efficient and accurate methods are needed to automatically segmenting organs-at-risk (OAR) to accelerate the radiotherapy workflow and decrease the treatment wait time. We developed and evaluated the use of a fused model Dense V-Network for its ability to accurately segment pelvic OAR. We combined two network models, Dense Net and V-Net, to establish the Dense V-Network algorithm. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1775290DOI Listing

Variation in cancer survival between hospital districts and within them in Finland.

Acta Oncol 2020 Jun 18:1-6. Epub 2020 Jun 18.

Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland.

Monitoring regional variation in population-based cancer survival is useful for assessing equity in national health-care system. This study quantifies variation in survival between municipalities and hospital districts responsible for primary care and for specialised care, respectively, in Finland. Five-year relative survival of 11 cancers and close to 700,000 patients was estimated by municipality in Finland over 1962-2016 using hierarchical Bayesian modelling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1772500DOI Listing

An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry.

Acta Oncol 2020 Jun 16:1-8. Epub 2020 Jun 16.

Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre +, Maastricht, The Netherlands.

In 2013, eribulin was reimbursed under a coverage with evidence development (CED) as third or later chemotherapy line for advanced breast cancer (ABC) patients in the Netherlands because of uncertain cost effectiveness. In 2016, the final decision of reimbursing eribulin was taken without considering the evidence collected during CED research. We analysed the cost effectiveness of eribulin versus non-eribulin chemotherapy, using real-world data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1775289DOI Listing

Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC.

Acta Oncol 2020 Jun 16:1-7. Epub 2020 Jun 16.

Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.

Two phase III trials show that maintenance pemetrexed therapy after platinum-doublet chemotherapy prolongs overall survival (OS) and progression free survival (PFS) in advanced non-squamous non-small-cell lung cancer (NSCLC). However, few patients in the control arms received pemetrexed at progression in these trials, performance status (PS) two patients were ineligible and few of the participants were elderly. Thus, we designed this study comparing immediate switchmaintenance pemetrexed therapy with pemetrexed at progression after platinum-doublet chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1778179DOI Listing

Radiotherapy treatment volumes for oligorecurrent nodal prostate cancer: a systematic review.

Acta Oncol 2020 Jun 13:1-11. Epub 2020 Jun 13.

Department of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland.

Radiotherapy is an emerging treatment strategy for nodal oligorecurrent prostate cancer (PCa) patients. However, large heterogeneities exist in the RT regimens used, with series reporting the use of elective nodal radiotherapy (ENRT) strategies and others the delivery of focal treatments to the relapsing nodes with Stereotactic Body Radiotherapy (SBRT). In this systematic review of the literature we compared the oncological outcomes and toxicity of the different RT regimens for nodal oligorecurrent PCa patients, with the aim of defining the optimal RT target volume in this setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1775291DOI Listing
June 2020
2.997 Impact Factor

Patients' perspective in the context of proton beam therapy: summary of a Nordic workshop.

Acta Oncol 2020 Jun 13:1-6. Epub 2020 Jun 13.

ProtonCare Study Group.

On 15-16 November 2019, the Skandion Clinic in Sweden hosted the first Nordic workshop on 'Patients' perspective in proton beam therapy'. The workshop was conducted to describe and compare the patient care in PBT clinics in the Nordic countries and to initiate a collaboration, with the target to ensure patient participation and reduce the risk of inequity of access by lowering the barriers for accepting PBT in a distant clinic. The overarching aim of this workshop was to describe and compare the use of patients' perspectives in the Nordic PBT clinics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1762927DOI Listing

Oncological management of pregnancy-associated cancers: analysis from the French CALG (Cancer Associé à La Grossesse) network.

Acta Oncol 2020 Jun 11:1-8. Epub 2020 Jun 11.

Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), University Pierre-et-Marie-Curie Paris VI, Institut Universitaire de Cancérologie (IUC), Paris, France.

Pregnancy-associated cancers constitute a major medical challenge. The objective of this study was to describe their epidemiological, oncological and obstetrical outcomes from the French CALG (Cancer Associé à La Grossesse) network. Retrospective analysis of patients diagnosed with a cancer associated with pregnancy between January 2015 and December 2018 after advice from the CALG network. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1767300DOI Listing

Choices.

Authors:
Vanita Noronha

Acta Oncol 2020 Jul 11;59(7):797-798. Epub 2020 Jun 11.

Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.

We need to make choices on a daily basis in our practice of medical oncology. In regular times, these choices are evidence-based and backed by science. However, during emergency situations like the current COVID pandemic, these choices are not just tougher to make, but come with the added burden of inadequate evidence to base them on. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1777325DOI Listing

The influence of socioeconomic position on adjuvant treatment of stage III colon cancer: a systematic review and meta-analysis.

Acta Oncol 2020 Jun 11:1-9. Epub 2020 Jun 11.

Department of Oncology, Copenhagen University Hospital, Herlev and Gentofte, Denmark.

Patients with colon cancer (CC) with low socioeconomic position (SEP) have a worse survival than patients with high SEP. We investigated the association between different socioeconomic indicators and the steps in the treatment trajectory leading to initiation of adjuvant chemotherapy (ACT) for patients with stage III CC. A systematic review and meta-analyses were conducted in accordance with the MOOSE checklist. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1772501DOI Listing

Long-term bowel dysfunction after right-sided hemicolectomy for cancer.

Acta Oncol 2020 Jun 5:1-6. Epub 2020 Jun 5.

Department of Surgery, Aarhus University Hospital, Aarhus, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1772502DOI Listing

Impact of bowel and rectum air on target dose with robustly optimized intensity-modulated proton therapy plans.

Acta Oncol 2020 Jun 5:1-7. Epub 2020 Jun 5.

Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.

Pelvic target dose from intensity-modulated proton therapy (IMPT) is sensitive to patient bowel motion. Robustly optimized plans in regard to bowel filling may improve the dose coverage in the treatment course. Our purpose is to investigate the effect of air volume in large and small bowel and rectum on target dose from IMPT plans. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1769859DOI Listing
June 2020
2.997 Impact Factor

Patient-reported outcomes regarding radiation therapy in patients with multiple myeloma.

Acta Oncol 2020 Jun 4:1-5. Epub 2020 Jun 4.

Radiation Oncology Department, Moffitt Cancer Center & Research Institute, Tampa, FL, USA.

Radiation therapy (RT) has been widely used for palliation in multiple myeloma. However, no data exist on symptom assessment and patient-reported outcomes regarding the efficacy of RT in this disease process. This study aims to demonstrate the impact of palliative RT on patient-reported symptoms in patients with multiple myeloma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1772499DOI Listing

Survival after breast cancer in women with type 2 diabetes using antidiabetic medication and statins: a retrospective cohort study.

Acta Oncol 2020 Jun 1:1-8. Epub 2020 Jun 1.

Research Unit of Mathematical Sciences, University of Oulu, Oulu, Finland.

We assessed survival of breast cancer in women with type 2 diabetes (T2D) treated with metformin, other types of antidiabetic medication (ADM) and statins. The study cohort consisted of women with T2D and diagnosed with breast cancer in Finland in 1998─2011. Mortality rates from breast cancer and other causes were analysed by Cox models, and adjusted hazard ratios (HRs) with 95% confidence intervals (Cls) were estimated in relation to the use of different types of medication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1769858DOI Listing

A systematic review of the role of carbon ion radiation therapy in recurrent rectal cancer.

Acta Oncol 2020 Jun 1:1-6. Epub 2020 Jun 1.

Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, FL, USA.

Colorectal cancer is the fourth leading cause of cancer-associated death in the world. The 5-year local recurrence rates in patients undergoing multimodality therapy are approximately 5-10%. The standard approach to treat locally recurrent rectal is re-irradiation followed by surgical resection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1769184DOI Listing
June 2020
2.997 Impact Factor

Health-related quality of life and symptom burden of epithelioid hemangioendothelioma patients: a global patient-driven Facebook study in a very rare malignancy.

Acta Oncol 2020 Jun 1:1-8. Epub 2020 Jun 1.

Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Epithelioid hemangioendothelioma (EHE) is an ultra-rare vascular sarcoma with unique clinical features. EHE is characterized by an unpredictable, often protracted, clinical course and highly variable clinical presentation. Due to difficulty recruiting ultra-rare cancer patients, health-related quality of life (HRQoL) of EHE patients has not yet been studied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1766696DOI Listing

Comorbidity and early death in Danish stage I lung cancer patients - an individualised approach.

Acta Oncol 2020 May 28:1-8. Epub 2020 May 28.

Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark.

Comorbidity is an important prognostic marker and a treatment indicator for lung cancer patients. Register-based studies often describe the burden of comorbidity by the Charlson comorbidity index (CCI) based on hospital discharge data. We assessed the association between somatic and psychiatric comorbidity and death within one year in early lung cancer and, furthermore, the burden of comorbidity according to treatment type. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1764096DOI Listing

Desloratadine and loratadine stand out among common H-antihistamines for association with improved breast cancer survival.

Acta Oncol 2020 May 27:1-7. Epub 2020 May 27.

Department of Cancer Epidemiology, Clinical Sciences, Lund University, Lund, Sweden.

As tumors maintain an inflammatory microenvironment, anti-inflammatory medication can be useful in cancer therapy. We have previously shown an association with improved survival in melanoma for use of the H-antihistamines desloratadine and loratadine, and here we examine use of H-antihistamines and breast cancer mortality. We investigated use of the six major H-antihistamines (cetirizine, clemastine, desloratadine, ebastine, fexofenadine and loratadine) and breast cancer-specific and overall mortality in a nation-wide register-based study of all 61,627 Swedish women diagnosed with breast cancer 2006-2013. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1769185DOI Listing

The effect of radiation therapy on the objective response and outcomes with nivolumab for hepatocellular carcinoma.

Acta Oncol 2020 May 22:1-4. Epub 2020 May 22.

Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1769860DOI Listing
May 2020
2.997 Impact Factor

Metastasis directed treatment of brain metastases from colorectal cancer - a Danish population-based cohort study.

Acta Oncol 2020 May 22:1-5. Epub 2020 May 22.

Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus N, Denmark.

Brain metastases (BMs) are an uncommon presentation of metastatic colorectal cancer (mCRC) with reported incidence of about 2-4%. Today, there is an increased awareness towards a metastasis directed treatment approach with either surgical resection, stereotactic radiotherapy (SRT) or both. We examined patient characteristics and survival for patients treated with a localized modality for BM from CRC in a nationwide population-based study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1769861DOI Listing

Target miss using PTV-based IMRT compared to robust optimization via coverage probability concept in prostate cancer.

Acta Oncol 2020 May 21:1-7. Epub 2020 May 21.

Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany.

Cure- and toxicity rates of prostate IGRT can both be affected by ill-chosen planning target volume (PTV) margins. For dose-escalated prostate radiotherapy, we studied the potential for organ at risk (OAR) sparing and compensation of prostate motion with robust plan optimization using the coverage probability (CovP) concept compared to conventional PTV-based IMRT. We evaluated plan quality of CovP-plans for 27 intermediate risk prostate cancer patients treated in a prospective study (78 Gy/39 fractions). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1760349DOI Listing

First system for fully-automated multi-criterial treatment planning for a high-magnetic field MR-Linac applied to rectal cancer.

Acta Oncol 2020 May 21:1-7. Epub 2020 May 21.

Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

In this study we developed a workflow for fully-automated generation of deliverable IMRT plans for a 1.5 T MR-Linac (MRL) based on contoured CT scans, and we evaluated automated MRL planning for rectal cancer. The Monte Carlo dose calculation engine used in the clinical MRL TPS (Monaco, Elekta AB, Stockholm, Sweden), suited for high accuracy dose calculations in a 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1766697DOI Listing

Cancer patients' preferred and perceived level of involvement in treatment decision-making: an epidemiological study.

Acta Oncol 2020 May 19:1-8. Epub 2020 May 19.

Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

We aimed to analyze preferred and perceived levels of patients' involvement in treatment decision-making in a representative sample of cancer patients. We conducted a multicenter, epidemiological cross-sectional study with a stratified random sample based on the incidence of cancer diagnoses in Germany. Data were collected between January 2008 and December 2010. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1762926DOI Listing

Clinical implications of variable relative biological effectiveness in proton therapy for prostate cancer.

Acta Oncol 2020 May 19:1-7. Epub 2020 May 19.

Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.

To study the potential consequences of differences in the evaluation of variable versus uniform relative biological effectiveness calculations in proton radiotherapy for prostate cancer. Experimental data with proton beams suggest that relative biological effectiveness increases with linear energy transfer. This relation also depends on the [Formula: see text] ratio, characteristic of a tissue and a considered endpoint. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1762928DOI Listing

Increase of cervical cancer incidence in Sweden in relation to screening history: population cohort study.

Acta Oncol 2020 May 18:1-6. Epub 2020 May 18.

Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

Cervical cancer incidence in Sweden decreased from 24/100,000 in 1965 to 8/100,000 in 2011, but has from 2014 increased to 11/100,000. The increase appears to correlate to screening history. We perform a study of the cancer risk change in relation to screening history over two screening rounds to verify the correlation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1764095DOI Listing

A novel energy sequence optimization algorithm for efficient spot-scanning proton arc (SPArc) treatment delivery.

Acta Oncol 2020 May 18:1-8. Epub 2020 May 18.

Department of Radiation Oncology, Beaumont Health System, Royal Oak, MI, USA.

Spot-scanning proton arc therapy (SPArc) has been proposed to improve dosimetric outcome and to simplify treatment workflow. To efficiently deliver a SPArc plan, it's crucial to minimize the number of energy layer switches (ELS) a sending because of the magnetic hysteresis effect. In this study, we introduced a new SPArc energy sequence optimization algorithm (SPArc_seq) to reduce ascended ELS and to investigate its impact on the beam delivery time (BDT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1765415DOI Listing

Negative illness perceptions are related to more fatigue among haematological cancer survivors: a PROFILES study.

Acta Oncol 2020 May 15:1-8. Epub 2020 May 15.

Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.

: The common sense model provides a theoretical framework for understanding substantial fatigue among (haematological) cancer survivors based on their illness perceptions. We therefore examined the associations between modifiable illness perceptions and substantial fatigue while controlling for sociodemographic, clinical, and psychological factors (symptoms of depression and anxiety) among haematological cancer survivors.: Data from the population-based PROFILES registry were used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1759823DOI Listing

Tumour control probability after Ruthenium-106 brachytherapy for choroidal melanomas.

Acta Oncol 2020 May 15:1-8. Epub 2020 May 15.

Department of Ophthalmology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

Ruthenium-106 (Ru-106) brachytherapy is a common eye-preserving treatment for choroidal melanomas. However, a dose-response model describing the relationship between the actual delivered tumour dose and tumour control has, to the best of our knowledge, not previously been quantified for Ru-106 brachytherapy; we aimed to rectify this. We considered consecutive patients with primary choroidal melanomas, treated with Ru-106 brachytherapy (2005-2014). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1762925DOI Listing

Rate of locoregional recurrence among patients with oropharyngeal squamous cell carcinoma with known HPV status: a systematic review.

Acta Oncol 2020 May 14:1-6. Epub 2020 May 14.

Department of Otorhinolaryngology, Head and Neck Surgery, and Audiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

We aimed to review systematically the literature on locoregional recurrence rates in patients with HPV-positive and -negative oropharyngeal squamous cell carcinoma (OPSCC). PubMed and Embase databases were systematically searched using key words such as human papillomavirus, oropharyngeal squamous cell carcinoma with local, regional, and locoregional recurrence. Nine studies (2974 patients with known HPV-status, 59% HPV-positive) were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1759822DOI Listing

National e-library for standardized chemotherapy regimens.

Acta Oncol 2020 May 13:1-5. Epub 2020 May 13.

Ergonomics and Aerosol Technology, Department of Design Sciences, Faculty of Engineering LTH, Lund University, Lund, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1764097DOI Listing

Socioeconomic inequalities in gastric cancer incidence in Canada: 1992-2010.

Acta Oncol 2020 May 13:1-5. Epub 2020 May 13.

School of Health Administration, Dalhousie University, Halifax, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1764098DOI Listing

Maintenance therapy and drug holiday in sarcoma patients: systematic review.

Acta Oncol 2020 May 13:1-7. Epub 2020 May 13.

Medical School, Lille University, Lille, France.

Overall prognosis of advanced sarcoma remains poor, optimization of systemic treatment is urgently needed in this setting. We systematically reviewed fully published English-speaking literature about maintenance therapy and drug holiday in sarcoma patients management. We found that switch maintenance therapy with cyclophosphamide/vinorelbine improves the outcome of localized high-risk rhabdomyosarcoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1759825DOI Listing

Tumor volume regression during neoadjuvant chemoradiotherapy for esophageal cancer: a prospective study with weekly MRI.

Acta Oncol 2020 Jul 13;59(7):753-759. Epub 2020 May 13.

Department of Radiation Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Neoadjuvant chemoradiotherapy (nCRT) for esophageal cancer causes tumor regression during treatment. Tumor regression can induce changes in the thoracic anatomy, with smaller target volumes and displacement of organs at risk (OARs) surrounding the tumor as a result. Adaptation of the radiotherapy treatment plan according to volumetric changes during treatment might reduce radiation dose to the OARs, while maintaining adequate target coverage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1759819DOI Listing

Image-guided hypofractionated double-scattering proton therapy in the management of centrally-located early-stage non-small cell lung cancer.

Acta Oncol 2020 May 12:1-7. Epub 2020 May 12.

Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA.

The treatment of centrally-located early-stage non-small cell lung cancer (NSCLC) with image-guided stereotactic body radiotherapy (SBRT) is challenging due to the proximity of critical normal structures to the tumor target. The purpose of this study was to report the results of our experience in treating centrally-located early-stage NSCLC with hypofractionated proton therapy (PT). Between 2009 and 2018, 23 patients with T1-T2N0M0 NSCLC (T1, 46%; T2, 54%) were treated with image-guided hypofractionated double-scattering PT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1759821DOI Listing

Early progression of breast cancer during neoadjuvant chemotherapy may predict poorer prognoses.

Acta Oncol 2020 May 12:1-7. Epub 2020 May 12.

Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.

In Finland, breast cancers treated with neoadjuvant chemotherapy (NACT) are usually locally advanced and/or have an inflammatory phenotype. We evaluated early NACT responses in breast tumours and lymph nodes and their correlation with survival. We collected a retrospective dataset of 145 patients with very high-risk but non-metastasised breast cancers that were treated with NACT in a Finnish University Hospital between September 2013 and January 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1760350DOI Listing

The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma - a substudy of the SORAMIC trial.

Acta Oncol 2020 May 5:1-8. Epub 2020 May 5.

Department of Medical Oncology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.

: Sorafenib for advanced hepatocellular carcinoma (HCC) is dose adjusted by toxicity. Preliminary studies have suggested an association between plasma concentrations of sorafenib and its main metabolite (M2) and clinical outcomes. This study aimed to validate these findings and establish target values for sorafenib trough concentrations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1759826DOI Listing

Adherence to treatment guidelines and survival in older women with early-stage breast cancer in Denmark 2008-2012.

Acta Oncol 2020 Jul 4;59(7):741-747. Epub 2020 May 4.

Department of Oncology, Odense University Hospital, Odense, Denmark.

The aims of this study were to compare patients 70 years or older with younger patients, to examine whether Danish patients with early-stage breast cancer aged 70 years or more received treatment according to guidelines, the reasons for deviating from the guidelines, and to analyze whether such deviations affected survival. From the Danish Breast Cancer Cooperative Group (DBCG) database we identified 23,247 women diagnosed with early-stage breast cancer in Denmark from 2008 to 2012. 17,391 were aged less than 70 years and 5856 were 70+ years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1757148DOI Listing

Predictive pharmacogenetic biomarkers for breast cancer recurrence prevention by simvastatin.

Acta Oncol 2020 Apr 30:1-7. Epub 2020 Apr 30.

Department of Clinical Epidemiology, Aarhus University Hospital/Randers Regional Hospital, Aarhus, Denmark.

Statins treat hyperlipidemia and prevent cardiovascular morbidity and mortality. Evidence suggests that they also have anti-neoplastic activity. Several studies show a reduced rate of breast cancer recurrence among lipophilic statin users (, simvastatin), motivating calls for clinical trials of statins in breast cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1759820DOI Listing

Results of neoadjuvant chemo(radio)therapy and resection for stage IIIA non-small cell lung cancer in The Netherlands.

Acta Oncol 2020 Jul 29;59(7):748-752. Epub 2020 Apr 29.

Department of Surgery, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

Concurrent chemoradiotherapy remains the main treatment strategy for patients with stage IIIA non-small cell lung cancer (NSCLC); stage cT3N1 or cT4N0-1 may be eligible for surgery and potentially resectable stage IIIA (N2) NSCLC for neoadjuvant therapy followed by resection. We evaluated treatment patterns and outcomes of patients with stage IIIA NSCLC in The Netherlands. Primary treatment data of patients with clinically staged IIIA NSCLC between 2010 and 2016 were extracted from The Netherlands Cancer Registry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1757150DOI Listing

Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000-1.

Acta Oncol 2020 Jul 29;59(7):825-832. Epub 2020 Apr 29.

Department of Oncology, Gävle Hospital, Sweden.

Retrospective studies have suggested that chemotherapy-induced leukopenia is associated with improved recurrence-free or overall survival. The SBG 2000-1 trial was designed to verify the favorable prognosis associated with chemotherapy-induced leukopenia in early breast cancer. Patients not experiencing chemotherapy-induced leukopenia were randomized into standard dosed or individually escalated chemotherapy doses based on the grade of leukopenia after a first standard dose. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1757149DOI Listing

Long-term outcome in patients operated with hybrid esophagectomy for esophageal cancer - a cohort study.

Acta Oncol 2020 Jul 23;59(7):859-865. Epub 2020 Apr 23.

Department of Gastrointestinal and Pediatric Surgery, Oslo University Hospital, Oslo, Norway.

Over the past two decades, hybrid and total minimally invasive esophagectomy for esophageal cancer (EC) has increasingly been implemented with the aim to improve morbidity, functional result and ultimately the prognosis in these patients. However, more results are warranted and in this single-center study we report long-time outcome in a cohort of cancer patients treated with hybrid esophagectomy (HE). Hundred and nine patients with EC operated with HE from November 2007 to June 2013 were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1750694DOI Listing

Socioeconomic inequalities in stage-specific breast cancer incidence: a nationwide registry study of 1.1 million young women in Norway, 2000-2015.

Acta Oncol 2020 Apr 22:1-7. Epub 2020 Apr 22.

Cancer Registry of Norway, Oslo, Norway.

Women with high socioeconomic status (SES) have the highest incidence rates of breast cancer. We wanted to determine if high SES women only have higher rates of localized disease, or whether they also have higher rates of non-localized disease. To study this, we used data on a young population with universal health care, but not offered screening. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1753888DOI Listing

A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer.

Acta Oncol 2020 Apr 22:1-9. Epub 2020 Apr 22.

Department of Surgery, Catharina Hospital Eindhoven, Eindhoven, The Netherlands.

Proximal esophageal cancer (EC) is commonly treated with definitive chemoradiation (CRT). The radiation dose and type of chemotherapy backbone are still under debate. The objective of this study was to compare the treatment outcomes of contemporary CRT regimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1753889DOI Listing